Results 71 to 80 of about 7,268 (227)

Molecular Design of Cyclic Peptides with Cell Membrane Permeability and Development of MDMX-p53 Inhibitor.

open access: yesACS Medicinal Chemistry Letters, 2023
Cyclic peptides have been expected to be one of the modalities of intracellular protein-protein interaction (PPI) inhibitors, but they are generally known to have low cell membrane permeability.
Mai Mizuno-Kaneko   +7 more
semanticscholar   +1 more source

MDM2-ALT1 and MDMX-ALT2 interact with full-length MDM2 and MDMX.

open access: yes, 2014
A. Full-length MDM2 is encoded by exons 3 to 12 of the MDM2 gene and consists of the N-terminal p53-binding domain, the nuclear localization (NLS) and export signals (NES), the central ARF binding and Zinc finger domains and the C-terminal RING domain ...
Thomas W. Bebee (611924)   +6 more
core   +1 more source

MDM2 Promotes Ubiquitination and Degradation of MDMX [PDF]

open access: yesMolecular and Cellular Biology, 2003
The p53 tumor suppressor is regulated by MDM2-mediated ubiquitination and degradation. Mitogenic signals activate p53 by induction of ARF expression, which inhibits p53 ubiquitination by MDM2. Recent studies showed that the MDM2 homolog MDMX is also an important regulator of p53.
Yu, Pan, Jiandong, Chen
openaire   +2 more sources

Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy Methods.

open access: yesPLoS ONE, 2015
The p53-MDMX interaction has attracted extensive attention of anti-cancer drug development in recent years. This current work adopted molecular dynamics (MD) simulations and cross-correlation analysis to investigate conformation changes of MDMX caused by
Shuhua Shi   +2 more
doaj   +1 more source

Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells

open access: yesBreast Cancer Research, 2019
Introduction Many human breast cancers overexpress the E3 ubiquitin ligase MDM2 and its homolog MDMX. Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα+) breast cancer and triple-negative breast cancer (TNBC).
Chong Gao   +5 more
doaj   +1 more source

Self‐Assembly of Therapeutic Peptides for Enhanced Cancer Therapy: Strategies, Therapeutic Performance, and Future Perspectives

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Therapeutic peptide self‐assembly is governed by multiple non‐covalent interactions, enabling the construction of diverse supramolecular structures. These self‐assembled systems can be engineered through spontaneous self‐assembly of monomers, co‐assembly, or stimulus‐responsive strategies to improve tumor delivery efficiency.
Yuelin Fang   +6 more
wiley   +1 more source

RPL37, RPS15, and RPS20 bind to and regulate MdmX levels.

open access: yes, 2013
(a–c) Association of RPs and MdmX. H1299 cells were transfected with HA-MdmX (0.5 µg), Myc-RP (1.2 µg), or both. (GFP was added as a control for transfection efficiency.) Ectopic MdmX and RP levels were detected by immunoblotting with α-MdmX and α-Myc ...
Xavier Jacq (433920)   +3 more
core   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

rHSA-P53i and rHSA-PMI bind to MDM2 and MDMX.

open access: yes, 2013
To detect the interaction between MDM2/MDMX and rHSA fusion proteins, 4 µg each of biotinylated rHSA (lane 1), rHSA-P53i (lane 2), or rHSA-PMI (lane 3) were added to 200 µg of SJSA-1 whole cell lysate.
Zhiyu Li (10983)   +3 more
core   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

open access: yesAdvanced Science, Volume 13, Issue 60, 28 October 2026.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy